Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
|Glossary of Terms for Supplement|
Carcinogenic = producing or tending to produce cancer
Genotoxic = damaging to genetic material such as DNA and chromosomes
Mutagenic = inducing or capable of inducing genetic mutation
Teratogenic = interfering with fetal development and resulting in birth defects
For information regarding the protease inhibitor (PI) class of drugs and potential metabolic complications during pregnancy and pregnancy outcome, see Combination Antiretroviral Drug Regimens and Pregnancy Outcome.
Atazanavir (Reyataz, ATV)
Darunavir (Prezista, DRV)
Fosamprenavir (Lexiva, FPV)
Indinavir (Crixivan, IDV)
Lopinavir/Ritonavir (Kaletra, LPV/r)
Nelfinavir (Viracept, NFV)
Saquinavir (Invirase [Hard Gel Capsule], SQV)
Tipranavir (Aptivis, TPV)